Randomized, observer-blind, placebo-controlled, four Parallel Group, Clinical Trial for exploring the Efficacy and Tolerability of two different strengths ketotifen nasal spray (Ketotifen 0.025 mcg/ml and 0.050 mcg/ml) vs sodium cromoglicate nasal spray 2% in Patients with Rhinitis

Condition studied

Rhinitis

Investigational medicinal product(s)

Eligibility

Primary endpoint

Change in VAS score in the patient symptom sumscore [from final visit (week 12) to baseline]

Endpoint detail

Change in VAS score in the patient symptom sumscore [from follow-up visit (week 4) to baseline], Change in iTNSS from final visit (week 12) to baseline, Change in iTNSS from follow-up visit (week 4) to baseline, Change in ARS score from final visit (week 12) to baseline, Change in ARS score from follow-up visit (week 4) to baseline